140
Participants
Start Date
July 10, 2017
Primary Completion Date
November 16, 2020
Study Completion Date
November 16, 2020
APX005M
APX005M is a CD40 agonistic monoclonal antibody
Nivolumab
Nivolumab is an immune checkpoint (PD-1) blocking antibody
SUNY Upstate Medical Hospital, Syracuse
Fox Chase Center, Rockledge
Abramson Cancer Center of The University of Pennsylvania, Philadelphia
Fox Chase Cancer Center, Philadelphia
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore
H. Lucus Augusti, Lugo
H. Doce de Octubre, Madrid
H. HM Sanchinnarro, Madrid
H. de Málaga, Málaga
Hem-Onc Associates of the Treasure Coast, Port Saint Lucie
Tennessee Oncology, Nashville
University Hospitals Seidman Cancer Center, Cleveland
H. La Fe, Valencia
H. General de Valencia, Valencia de Alcántara
Nebraska Cancer Specialists, Omaha
University of Nebraska Medical Center, Omaha
University of Arizona Cancer Center, Tucson
City of Hope, Duarte
Yale University, New Haven
Hospital Quirón Dexeus, Barcelona
H. Vall d'Hebron, Barcelona
H. Clinic i Provincial, Barcelona
H. Insular de Gran Canaria, Las Palmas de Gran Canaria
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Apexigen America, Inc.
INDUSTRY